Pharmacoeconomic review report : Ixekizumab (Taltz)

Pharmacoeconomic review report Ixekizumab (Taltz)

Ixekizumab (Taltz) is a humanized anti-interleukin (IL)-17A monoclonal antibody indicated for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for systematic therapy or phototherapy. The manufacturer is requesting listing of ixekizumab for adult patients in...

Full description

Bibliographic Details
Main Author: Canadian Agency for Drugs and Technologies in Health (author)
Corporate Author: Canadian Agency for Drugs and Technologies in Health, author, issuing body (author)
Format: eBook
Language:Inglés
Published: Ottawa (ON) : CADTH 2017.
Series:Common drug review clinical review report.
Subjects:
Anti-inflammatory agents.
See on Biblioteca Universitat Ramon Llull:https://discovery.url.edu/permalink/34CSUC_URL/1im36ta/alma991009820269406719
Table of Contents:
  • Abbreviations
  • Executive Summary
  • Information on the Pharmacoeconomic Submission
  • Summary of the manufacturer's pharmacoeconomic submission
  • Manufacturer's base case
  • Summary of manufacturer's sensitivity analyses
  • Limitations of manufacturer's submission
  • CADTH Common Drug Review Reanalyses
  • CADTH CDR Price-Reduction Analysis
  • Conclusions
  • APPENDIX 1. Cost Comparison
  • APPENDIX 2. Summary of Key Outcomes
  • APPENDIX 3. Additional Information
  • APPENDIX 4. Reviewer Worksheets
  • References.

Similar Items